EUCTR2009-017872-26-IT进行中（未招募）不适用
Role and pharmacological modulation of lug inflammation in chronic obstructive pulmonary disease (COPD) - ND
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI0 个研究点开始时间: 2010年1月29日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patient is male or female, at least 40 years of age and no more than 85 years. 2. Patient has mild, moderate or severe COPD according to the GOLD guidelines with a FEV1/FVC < 70% and FEV1 > 30% of the predicted value. 3. Reversibility to short-acting beta-agonists (SABA) of less than 200 ml or less than 12% predicted value FEV1 4. No acute exacerbations in the previous 3 months 5. No history of systemic disease or other pulmonary disease 6. No treatment with inhaled or systemic glucocorticoids in the previous 3 weeks. 7. No history of asthma or atopic disease 8. Current treatment for COPD includes SABA alone as needed; patients on tiotropium before the beginning of the study will continue tiotropium; patients on a different antimuscarinic drug before the beginning of the study will continue bronchodilating treatment with tiotropium; patients on a LABA before the beginning of the study, will continue bronchodilating treatment with tiotropium 9. Ability to perform reproducible spirometry. 10. Patient is a nonsmoker and has stopped smoking for at least one year. 11. Ability of patient to provide informed consent, as evidenced by signing a copy of the consent form approved by the institutional review board of the subject s respective study institution.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •General 1. Patient is, in the opinion of the investigator, mentally or legally incapacitated preventing informed consent from being obtained, or cannot read or comprehend written material. 2. Patient is hospitalized. 3. Patient has undergone any major surgical procedure in the previous four weeks. 4. Patient has participated in a clinical trial involving an investigational or marketed drug in the previous four weeks. 5. Subjects who were smokers in the previous year. Pulmonary 1. Patient has, in addition to COPD, any active, acute or chronic pulmonary disorder documented by history or physical examination. 2. Patient has ever been intubated for COPD, has required acute COPD therapy treated in an emergency room/urgent care facility/office setting within one month or has been hospitalized for COPD in the previous three months or required 2 or more hospitalizations for COPD in the past year. 3. Patient had an upper respiratory tract infection (URI) in the previous three weeks. General Medical 1. Patient is hypersensitive to tiotropium, fluticasone or their components. 2. Patient has a clinically significant, active disease of the gastrointestinal, cardiovascular, hepatic, neurological, renal, genitourinary, or hematological systems, or has uncontrolled hypertension (>160/95), or an immunodeficiency, or an autoimmune disorder. 3. Patiens with glaucoma. 4. Patients with benign prostatic hypertrophy or other causes of urinary obstruction. 5. Patient has a history of any illness that could be immediately life threatening (ventricular arrhythmia, neoplasia, incompletely cured or treated in the last three months, `brittle` diabetes mellitus), or would pose restriction on participation in the study. Medications 1. Patient has taken the following medications: 1) Oral, intravenous, intramuscular, intra-articular or inhaled corticosteroids in the previous 4 weeks with the exception of nasal corticosteroids administered on a continuous basis. 2) Antibiotics for 7 consecutive days in the previous 4 weeks. 3) IV gammaglobulin or immunosuppressants in the previous 4 weeks. 4) Beta-receptor-blocking agents (including ocular preparations) in individuals known to be sensitive to these compounds in the previous two weeks. Procedural 1. Patient is unable to perform acceptable, reproducible spirometry, and peak flow measurements. 2. Patient is unable or unwilling to comply with the study procedures.
研究者
相似试验
进行中（未招募）
1 期
Pharmacological modulation of inflammation and platelet activation in inflammatory bowel diseasesEUCTR2013-002143-29-ITPOLICLINICO GEMELLI1
进行中（未招募）
不适用
ntersuchung der antiinflammatorischen Eigenschaften von Clopidogrel im Vergleich zu Acetylsalicylsäure bei Patienten mit chronischer ischämischer KardiomyopathieDas Ziel dieser Untersuchung ist es, zu evaluieren, ob und welche antiinflammatorischen Effekte Clopidogrel 75 mg im Vergleich zu Acetylalicylsäure (ASS) 100 mg bei Patienten mit chronischer ischämischer Kardiomyopathie aufweist. Untersucht werden soll dieses mittels Evaluation der peripheren endothelialen Stickstoffmonoxid-(NO) Bioverfügbarkeit sowie durch Bestimmung der Spiegel zirkulierender Peroxidasen wie Myeloperoxidase (MPO) oder Xanthin Oxidase (XO).EUCTR2006-000001-27-DEniversitäres Herzzentrum, Klinik für Kardiologie und Angiologie
招募中
1 期
Inflammation and Colchicine use in patients with ESRF undergoing DialysisHaemodialysisInflammationRenal and Urogenital - Kidney diseaseInflammatory and Immune System - Other inflammatory or immune system disordersChronic Kidney DiseaseACTRN12617000922370A/Prof Sanjay Patel100
进行中（未招募）
不适用
Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral versus CentralPatients with osteoarthritis undergoing elective primary single hip arthroplastyEUCTR2005-003854-80-DEDepartment of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-University
尚未招募
不适用
Effect of omega-3 fatty acids on inflammation and blood vessel function in abdominal aortic aneurysmAbdominal aortic aneurysmACTRN12616000483459niversity of the Sunshine Coast50